NewAmsterdam Pharma's Q3 Net Loss Narrows, Revenue Grows

09:28 AM EST, 11/04/2026 (MT Newswires) -- NewAmsterdam Pharma (NAMS) reported a Q3 net loss of $0.14 per share on Wednesday, narrowing from a loss of $0.61 a year earlier. Analysts polled by FactSet expected a net loss of $0.42. Revenue for the quarter ended Sept. 30 was $19.2 million, compared with $348,000 a year earlier. Analysts expected $6.7 million. The biopharmaceutical company said that as of Sept. 30, it had $643.1 million in cash, cash equivalents and marketable securities.